Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crovalimab - Chugai Pharmaceutical/Roche

Next Previous
Search
Drug Profile

Crovalimab - Chugai Pharmaceutical/Roche

Alternative Names: Anti-C5 recycling antibody - Chugai Pharmaceutical/Roche; CH-7092230; Crovalimab-akkz; Piasky; RG 6107; RO 7092230; RO-7112689; RO-711269; RO7112689/F01; SKY-59

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche
  • Class Antianaemics; Monoclonal antibodies; Urologics
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Paroxysmal nocturnal haemoglobinuria
  • Phase III Atypical Haemolytic Uraemic Syndrome
  • Phase II Sickle cell anaemia
  • Discontinued Lupus nephritis

Most Recent Events

  • 07 Dec 2024 Adverse events and efficacy data from the phase-III COMMODORE-1 trial in Paroxysmal nocturnal hemoglobinuria presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024) ,
  • 07 Dec 2024 Efficacy and adverse events data from the phase III COMMODORE 2 trial in paroxysmal nocturnal hemoglobinuria presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 07 Dec 2024 Adverse events and efficacy data from a phase III COMMODORE 1 trial in Paroxysmal nocturnal haemoglobinuria presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top